How do helium-free MRI systems affect the total cost of ownership for neurodiagnostics?

Helium-free designs eliminate annual helium refill costs of USD 20,000–40,000 and remove the risk of quench-related downtime. The total five-year ownership costs drop by an estimated 25–30% compared with conventional superconducting magnets [13]. Read More

What interoperability standards should hospitals prioritize when procuring neurodiagnostic platforms?

DICOM, HL7 FHIR, and IHE-PCD profiles ensure seamless data exchange between imaging, EEG, and EHR systems. Procuring platforms certified against these standards reduces integration timelines from months to weeks [16]. Read More

How does reimbursement for blood-based Alzheimer's biomarkers differ across major markets?

The U.S. CMS is advancing national coverage for p-tau217, while European payers remain in health-technology-assessment phases. Japan's PMDA has granted breakthrough-device designation but has not finalized reimbursement codes [8]. Read More

What role do contract research organizations play in the Neurodiagnostics Market?

CROs manage centralized neuroimaging reads and EEG monitoring for multi-site clinical trials. Their demand scales with the CNS therapeutic pipeline, which includes over 600 active Phase II/III programs globally [10]. Read More

How are cybersecurity regulations shaping neurodiagnostic device design?

The FDA's 2023 cybersecurity guidance requires pre-market software bills of materials and patch-management plans. Vendors now embed encrypted data pipelines and zero-trust architectures into device firmware [5]. Read More

What procurement models are hospitals adopting for AI-enabled neurodiagnostic software?

Pay-per-study and SaaS subscription models are replacing perpetual licenses. These models lower upfront costs and align vendor revenue with hospital utilization rates [21]. Read More

How does the Neurodiagnostics Market address diagnostic access in rural and underserved regions?

Portable EEG kits, store-and-forward teleradiology, and mobile MRI trailers extend specialist-grade diagnostics to areas without permanent imaging infrastructure. Government subsidies in India and Brazil co-fund these deployments [9]. Read More

Neurodiagnostics Market (2025 - 2035)

ID: MRFR/MED/7290-HCR

90 Pages

Satyendra Maurya

Last Updated: July 02, 2026

Neurodiagnostics Market Research Report Information By Product Type (Diagnostic Imaging Systems, Clinical Diagnostic Instruments, and Reagents and Consumables), By Condition (Neurodegenerative Diseases, Stroke, Epilepsy, Headache Disorders, Sleep Disorders, and Others), By End User (Hospitals and Surgical Centers, Diagnostic Laboratories and Imaging Centers, Neurology Centers, Ambulatory Care Centers, and Research Laboratories and Academic Institutes) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

Neurodiagnostics Market

Market Size

Forecast Period2025-2035

CAGR (2025-2035)7.6%

2025 Market SizeUSD 9.78 billion

2035 Market SizeUSD 20.36 billion

Key Players

Siemens Healthineers

GE HealthCare

Philips Healthcare

Nihon Kohden

Natus Medical

Compumedics

Trends

Aging Population and Neurodegenerative Disease Burden
AI-Augmented Diagnostic Workflows
Blood-Based Biomarker Commercialization

Opportunities

Point-of-Care Neurodiagnostic Devices
Data Monetization and Real-World Evidence Platforms
Emerging-Market Hospital Digitization

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Aging Population and Neurodegenerative Disease Burden | |
  2. 3.1.2 AI-Augmented Diagnostic Workflow Adoption | |
  3. 3.1.3 Blood-Based Biomarker Commercialization | |
  4. 3.1.4 Government Neurotech Funding Programs | |
  5. 3.1.5 Telehealth and Remote Neurophysiology Monitoring | |
  6. 3.1.6 Reimbursement Expansion for Advanced Neuroimaging | |
  7. 3.1.7 Hospital Infrastructure Modernization in Emerging Economies |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 High Capital Cost of Neuroimaging Equipment | |
  2. 3.2.2 Fragmented Regulatory Pathways for AI Diagnostics | |
  3. 3.2.3 Reimbursement Uncertainty for Novel Biomarkers | |
  4. 3.2.4 Shortage of Trained Neurophysiology Technologists | |
  5. 3.2.5 Data Privacy and Interoperability Barriers |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Point-of-Care Neurodiagnostic Devices | |
  2. 3.3.2 Data Monetization and Real-World Evidence Platforms | |
  3. 3.3.3 Emerging-Market Hospital Digitization | |
  4. 3.3.4 Companion Diagnostics for Gene and Cell Therapies | |
  5. 3.3.5 Remote and Ambulatory Neurophysiology Monitoring |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Neurodiagnostics Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Product Type | |
  1. 5.1.1 Reagents & Consumables | |
  2. 5.1.2 Instruments & Systems | |
  3. 5.1.3 Software & Informatics | |
  4. 5.1.4 Gene Therapy Diagnostics |
2. 5.2 By Technology | |
  1. 5.2.1 Neuroimaging Technologies | |
  2. 5.2.2 Electrophysiology (EEG, EMG, EP) | |
  3. 5.2.3 Neuroinformatics & AI Analytics | |
  4. 5.2.4 Biomarker & Molecular Diagnostics |
3. 5.3 By Condition | |
  1. 5.3.1 Neurodegenerative Diseases | |
  2. 5.3.2 Cerebrovascular Disorders | |
  3. 5.3.3 Epilepsy & Seizure Disorders | |
  4. 5.3.4 Sleep Disorders | |
  5. 5.3.5 Traumatic Brain Injury & Others |
4. 5.4 By End User | |
  1. 5.4.1 Hospitals & Surgical Centers | |
  2. 5.4.2 Diagnostic Laboratories & Imaging Centers | |
  3. 5.4.3 Ambulatory Care & Emergency Settings | |
  4. 5.4.4 Research Institutions & CROs
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 Siemens Healthineers | |
  2. 7.3.2 GE HealthCare | |
  3. 7.3.3 Philips Healthcare | |
  4. 7.3.4 Nihon Kohden | |
  5. 7.3.5 Natus Medical (Integra LifeSciences) | |
  6. 7.3.6 Compumedics | |
  7. 7.3.7 Medtronic | |
  8. 7.3.8 Cadwell Industries | |
  9. 7.3.9 Masimo Corporation | |
  10. 7.3.10 BioSignal Group
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Autonomous Diagnostic Reporting |
2. 8.2 Platform Economics and Cloud Migration |
3. 8.3 Precision Neurology and Biomarker Convergence |
4. 8.4 Sustainability and Green Procurement
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Neurodiagnostics Market Size & Forecast, by Revenue (USD billion), 2021–2035 |
TABLE 2 Global Neurodiagnostics Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Global Neurodiagnostics Market – Driver Impact Analysis |
TABLE 4 Global Neurodiagnostics Market – Restraint Impact Analysis |
TABLE 5 Global Neurodiagnostics Market Size, by Product Type, 2021–2035 (USD billion) |
TABLE 6 Global Neurodiagnostics Market Size, by Technology, 2021–2035 (USD billion) |
TABLE 7 Global Neurodiagnostics Market Size, by Condition, 2021–2035 (USD billion) |
TABLE 8 Global Neurodiagnostics Market Size, by End User, 2021–2035 (USD billion) |
TABLE 9 Global Neurodiagnostics Market Size, by Region, 2021–2035 (USD billion) |
TABLE 10 North America Neurodiagnostics Market Size, by Country, 2021–2035 (USD billion) |
TABLE 11 Europe Neurodiagnostics Market Size, by Country, 2021–2035 (USD billion) |
TABLE 12 Asia-Pacific Neurodiagnostics Market Size, by Country, 2021–2035 (USD billion) |
TABLE 13 South America Neurodiagnostics Market Size, by Country, 2021–2035 (USD billion) |
TABLE 14 Middle East & Africa Neurodiagnostics Market Size, by Country, 2021–2035 (USD billion) |
TABLE 15 Competitive Benchmarking Matrix – Global Neurodiagnostics Market, 2025 |
TABLE 16 Company Profiles – Key Players, Global Neurodiagnostics Market |
TABLE 17 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 18 North America Neurodiagnostics Market Size, by Product Type, 2021–2035 (USD billion) |
TABLE 19 North America Neurodiagnostics Market Size, by Technology, 2021–2035 (USD billion) |
TABLE 20 North America Neurodiagnostics Market Size, by Condition, 2021–2035 (USD billion) |
TABLE 21 North America Neurodiagnostics Market Size, by End User, 2021–2035 (USD billion) |
TABLE 22 Europe Neurodiagnostics Market Size, by Product Type, 2021–2035 (USD billion) |
TABLE 23 Europe Neurodiagnostics Market Size, by Technology, 2021–2035 (USD billion) |
TABLE 24 Europe Neurodiagnostics Market Size, by Condition, 2021–2035 (USD billion) |
TABLE 25 Europe Neurodiagnostics Market Size, by End User, 2021–2035 (USD billion) |
TABLE 26 Asia-Pacific Neurodiagnostics Market Size, by Product Type, 2021–2035 (USD billion) |
TABLE 27 Asia-Pacific Neurodiagnostics Market Size, by Technology, 2021–2035 (USD billion) |
TABLE 28 Asia-Pacific Neurodiagnostics Market Size, by Condition, 2021–2035 (USD billion) |
TABLE 29 Asia-Pacific Neurodiagnostics Market Size, by End User, 2021–2035 (USD billion) |
TABLE 30 South America Neurodiagnostics Market Size, by Product Type, 2021–2035 (USD billion) |
TABLE 31 South America Neurodiagnostics Market Size, by Technology, 2021–2035 (USD billion) |
TABLE 32 South America Neurodiagnostics Market Size, by Condition, 2021–2035 (USD billion) |
TABLE 33 South America Neurodiagnostics Market Size, by End User, 2021–2035 (USD billion) |
TABLE 34 Middle East & Africa Neurodiagnostics Market Size, by Product Type, 2021–2035 (USD billion) |
TABLE 35 Middle East & Africa Neurodiagnostics Market Size, by Technology, 2021–2035 (USD billion) |
TABLE 36 Middle East & Africa Neurodiagnostics Market Size, by Condition, 2021–2035 (USD billion) |
TABLE 37 Middle East & Africa Neurodiagnostics Market Size, by End User, 2021–2035 (USD billion) |
TABLE 38 Report Scope & Methodology Summary |
TABLE 39 Detailed Sources and Citations
13 LIST OF FIGURES |
FIGURE 1 Global Neurodiagnostics Market Dynamics (Drivers, Restraints, Opportunities) |
FIGURE 2 Industry Value Chain Analysis — Neurodiagnostics Market |
FIGURE 3 Porter's Five Forces Analysis — Neurodiagnostics Market |
FIGURE 4 Global Neurodiagnostics Market Size Trend (USD billion), 2021–2035 |
FIGURE 5 Global Neurodiagnostics Market Share, by Product Type (2025) |
FIGURE 6 Global Neurodiagnostics Market Share, by Technology (2025) |
FIGURE 7 Global Neurodiagnostics Market Share, by Condition (2025) |
FIGURE 8 Global Neurodiagnostics Market Share, by End User (2025) |
FIGURE 9 Global Neurodiagnostics Market Share, by Region (2025) |
FIGURE 10 North America Neurodiagnostics Market Size Trend (USD billion), 2021–2035 |
FIGURE 11 Europe Neurodiagnostics Market Size Trend (USD billion), 2021–2035 |
FIGURE 12 Asia-Pacific Neurodiagnostics Market Size Trend (USD billion), 2021–2035 |
FIGURE 13 South America Neurodiagnostics Market Size Trend (USD billion), 2021–2035 |
FIGURE 14 Middle East & Africa Neurodiagnostics Market Size Trend (USD billion), 2021–2035 |
FIGURE 15 Competitive Landscape — Market Share Analysis (2025) |
FIGURE 16 Competitive Benchmarking Radar Chart — Top 10 Players

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
Product Type	Reagents & Consumables; Instruments & Systems; Software & Informatics; Gene Therapy Diagnostics	Reagents & Consumables	Gene Therapy Diagnostics
Neurodiagnostics Market	Neuroimaging Technologies; Electrophysiology (EEG, EMG, EP); Neuroinformatics & AI Analytics; Biomarker & Molecular Diagnostics	Neuroimaging Technologies	Neuroinformatics & AI Analytics
Condition	Neurodegenerative Diseases; Cerebrovascular Disorders; Epilepsy & Seizure Disorders; Sleep Disorders; Traumatic Brain Injury & Others	Neurodegenerative Diseases	Sleep Disorders
End User	Hospitals & Surgical Centers; Diagnostic Laboratories & Imaging Centers; Ambulatory Care & Emergency Settings; Research Institutions & CROs	Hospitals & Surgical Centers	Ambulatory Care & Emergency Settings
Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Product Type

Sub-Segment	Key Trend
Reagents & Consumables	Shift toward multiplex biomarker assay kits for neurodegenerative screening.
Instruments & Systems	Transition to helium-free MRI and portable EEG platforms
Software & Informatics	AI-driven automated reporting and cloud-based PACS integration.
Gene Therapy Diagnostics	Companion-diagnostic pairing with approved CNS gene therapies

The product-type segmentation reflects a market transitioning from hardware-centric capital sales toward a blended model where recurring consumable and software revenues provide greater revenue visibility and margin stability.

By Neurodiagnostics Market

Sub-Segment	Key Trend
Neuroimaging Technologies	AI-assisted MRI reconstruction enabling shorter scan times and higher throughput
Electrophysiology (EEG, EMG, EP)	Continuous wireless EEG monitoring expanding from the ICU to ambulatory settings
Neuroinformatics & AI Analytics	Cloud-native platforms aggregating multi-modal neurological data
Biomarker & Molecular Diagnostics	Plasma p-tau217 and neurofilament light assays nearing clinical-grade adoption

Neurodiagnostics Market segmentation highlights the tension between the large installed base of imaging hardware and the rapid value-creation potential of software and molecular platforms.

By Condition

Sub-Segment	Key Trend
Neurodegenerative Diseases	Blood-based early screening reduces reliance on PET imaging for Alzheimer's
Cerebrovascular Disorders	AI-powered CT angiography triage accelerating stroke-pathway decisions.
Epilepsy & Seizure Disorders	Long-term ambulatory EEG monitoring replacing short in-lab sessions
Sleep Disorders	Home polysomnography and wearable actigraphy are gaining payer acceptance.
Traumatic Brain Injury & Others	Point-of-care blood tests for concussion biomarkers entering clinical use

Condition-based segmentation underscores how diagnostic innovation is broadening the addressable patient population for each neurological category.

By End User

Sub-Segment	Key Trend
Hospitals & Surgical Centers	Integrated OR-to-ward neuromonitoring ecosystems
Diagnostic Laboratories & Imaging Centers	Outpatient referral volumes are growing with decentralized care models.
Ambulatory Care & Emergency Settings	Portable devices enabling field-level neurological triage
Research Institutions & CROs	Centralized neuroimaging core labs supporting multi-site CNS trials

End-user segmentation reflects a care-delivery shift from inpatient concentration toward distributed diagnostic access points, aligning with global trends in value-based and outpatient-first healthcare delivery.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”